Literature DB >> 23208738

Determining immunoassay cutoff value using Western blot results to predict hepatitis C infection in blood donors with low-titer anti-HCV reactivity.

Abdulkadir Kucukbayrak1, Saadet Cakmak, Ismail Necati Hakyemez, Tekin Tas, Hayrettin Akdeniz.   

Abstract

Since the 1990s, blood donors have been scanned for anti-hepatitis C virus (anti-HCV) antibodies, which can be defined by enzyme immunoassay as a screening test. In this population, false-reactive ratios have been high. Recently, some authors have aimed to find a cutoff value for anti-HCV different from those established by test manufacturers to predict HCV infection. In this study, 321 patients, after two repeating tests, had reactive results in s/co <10 titers on anti-HCV test. The patients were 29.6 % (n = 95) in women and 70.4 % (n = 226) in men. The patients were classified into three groups by Western blot (WB) results (PS, positive; NG, negative; and ID, indeterminate). The average anti-HCV titer of the whole group was 2.61 ± 1.96. Anti-HCV titers of subgroups were 2.43 ± 1.95 in NG, 4.93 ± 2.53 in PS, and 2.50 ± 1.65 in ID (p < 0.001). There was a significant difference between NG and PS and between PS and ID subgroups (p < 0.001). There was a positive correlation between WB and anti-HCV titers in all patients (r = 0.298, p < 0.001), in women (r = 0.282, p < 0.001), and in men (r = 0.337, p = 0.002). According to receiver operator characteristic curve analysis, the cutoff value of anti-HCV titer to predict hepatitis C infection was >2.61 s/co, with 74.1 % sensitivity and 71.6 % specificity (area under the curve, 0.820; 95 % confidence interval, 0.753 to 0.887). We suggest that an effective cutoff value for anti-HCV other than that established by the manufacturer cannot be assigned to predict hepatitis C infection for blood donors in low-prevalence areas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208738     DOI: 10.1007/s12223-012-0215-5

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  12 in total

1.  Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: overlap of false-positive reactivity and its impact on donor management.

Authors:  P Kiely; D Wilson
Journal:  Transfusion       Date:  2000-05       Impact factor: 3.157

2.  Chemiluminescence assay improves specificity of hepatitis C antibody detection.

Authors:  D Robert Dufour; Mageli Talastas; Maria D A Fernandez; Barbara Harris
Journal:  Clin Chem       Date:  2003-06       Impact factor: 8.327

3.  Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays.

Authors:  Clive R Seed; Angelo R Margaritis; Wayne V Bolton; Philip Kiely; Susan Parker; Lisa Piscitelli
Journal:  Transfusion       Date:  2003-02       Impact factor: 3.157

4.  Hepatitis C antibody intraassay correlation: is retest in duplicate necessary?

Authors:  Ana M Contreras; Erendi Tinoco; Alfredo Celis; Bárbara Novelo; M V Patricia Romero; Etelvina Carrada; Ricardo Jiménez-Méndez
Journal:  Transfusion       Date:  2007-09       Impact factor: 3.157

5.  False positive tests for anti-hepatitis C antibodies and the problem of notifying blood donors.

Authors:  S Bar-Shany; M S Green; E Shinar
Journal:  Int J Epidemiol       Date:  1996-06       Impact factor: 7.196

Review 6.  Diagnosis of hepatitis C virus (HCV) infection and laboratory monitoring of its therapy.

Authors:  S Erensoy
Journal:  J Clin Virol       Date:  2001-06       Impact factor: 3.168

7.  Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature.

Authors:  C Colin; D Lanoir; S Touzet; L Meyaud-Kraemer; F Bailly; C Trepo
Journal:  J Viral Hepat       Date:  2001-03       Impact factor: 3.728

8.  Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention.

Authors:  Miriam J Alter; Wendi L Kuhnert; Lyn Finelli
Journal:  MMWR Recomm Rep       Date:  2003-02-07

9.  Efficiency of the ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios.

Authors:  Margret Oethinger; Donald R Mayo; JoAnne Falcone; Pankaj K Barua; Brigitte P Griffith
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

10.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.